EurekaMag
+ Translate
+ Most Popular
The pigeon tick (Argas reflexus): its biology, ecology, and epidemiological aspects
Prevalence of hemoglobin abnormalities in Kebili (Tunisian South)
Lipogranuloma: a preventable complication of dacryocystorhinostomy
Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency
Bees from the Belgian Congo. The acraensis group of Anthophora
Placing gingival retraction cord
Total serum IgE, allergy skin testing, and the radioallergosorbent test for the diagnosis of allergy in asthmatic children
Acariens plumicoles Analgesoidea parasites des oiseaux du Maroc
Injuries of terminal phalanges of the fingers in children
Biology of flowering and nectar production in pear (Pyrus communis)
Das Reliktvorkommen der Aspisviper (Vipera aspis L.) im Schwarzwald
Hydrological modelling of drained blanket peatland
Pathologic morphology and clinical significance of the anomalous origin of the left circumflex coronary artery from the right coronary artery. General review and autopsy analysis of 30 cases
Cyto genetic analyses of lymphocyte cultures after exposure to calcium cyclamate
Axelrodia riesei, a new characoid fish from Upper Rio Meta in Colombia With remarks concerning the genus Axelrodia and description of a similar, sympatric, Hyphessobrycon-species
Favorable evolution of a case of tuberculosis of pancreas under antibiotic action
RIFM fragrance ingredient safety assessment, Valencene, CAS Registry Number 4630-07-3
Parenteral microemulsions: an overview
Temperate pasture: management for grazing and conservation
Evaluation of a new coprocessed compound based on lactose and maize starch for tablet formulation
Thermal expansion and cracking of three confined water-saturated igneous rocks to 800C
Revision of the genera of the tribe Stigmoderini (Coleoptera: Buprestidae) a discussion of phylogenetic relationships
Anal tuberculosis. Report of a case
Gastric tuberculosis in the past and present
Adaptive responses of the cardiovascular system to prolonged spaceflight conditions: assessment with Holter monitoring

Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia


Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia



La Clinica Terapeutica 122(1): 17-23



ISSN/ISBN: 0009-9074

PMID: 2973892

Thirty-eight patients with primary hypercholesterolemia have been treated with bezafibrate 200 mg t.i.d. after a period of dietary stabilization. After one month of bezafibrate treatment in type IIa patients, serum cholesterol fell on average by 20%, serum triglycerides by 25% apoB by 24% and apoA1 showed a slight but not significant increase. VLDL triglycerides decreased by 40%, LDL cholesterol by 24% and HDL cholesterol increased (7%) owing to the increase of the HDL3 cholesterol subfraction. In type IIb patients serum cholesterol decreased by 19%, serum triglycerides by 25%, and apoB by 29% while apoA1 increased by 19%, VLDL triglycerides decreased on average by 65% and LDL cholesterol by 20%. HDL cholesterol increased by 25% due to the increase of HDL2-cholesterol concentration while HDL3 cholesterol showed only a minor and non-significant increase. After 4 months the serum lipoprotein pattern was unchanged compared to that observed after 1 month of treatment. Changes in VLDL triglycerides, HDL cholesterol and apoA1 were greater in type IIb patients while those of LDL cholesterol and apoB were similar. Atherogenic indexes significantly decreased in both groups of patients. Modifications of lipoprotein patterns induced by bezafibrate are consistent with a reduction of cardiovascular risk in patients with type IIa and type IIb hyperlipoproteinemia.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039960512

Download citation: RISBibTeXText

Related references

Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia. European Journal of Clinical Pharmacology 37(6): 545-550, 1989

Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients. International Journal of Clinical Pharmacology Research 6(3): 249-253, 1986

Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Journal of the American College of Cardiology 32(6): 1648-1656, 1998

Effect of simvastatin on lipids apolipoproteins and lipoprotein particles in primary hypercholesterolemia. Stokes, J Iii And M Mancini (Ed ) Atherosclerosis Reviews, Vol 18 Hypercholesterolemia: Clinical And Therapeutic Implications; Symposium, Paris, France, December 4-5, 1987 Xv+202p Raven Press, Ltd : New York, New York, Usa Illus 153-160, 1988

Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia. European Journal of Clinical Pharmacology 30(2): 191-194, 1986

Effects of simvastatin on plasma lipids and apolipoproteins in primary hypercholesterolemia. Gotto, A M Jr , Et Al (Ed ) Treatment Of Severe Hypercholesterolemia in The Prevention Of Coronary Heart Disease; 2nd International Symposium, Munich, West Germany, June 29-30, 1989 Ix+274p S Karger Ag: Basel, Switzerland; New York, New York, Usa Illus 112-115, 1990

Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia. Lancet 1(8586): 611-613, 1988

Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia. Atherosclerosis 63(1): 57-64, 1987

Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia. Atherosclerosis 94(2-3): 241-248, 1992

Effects of simvastatin on plasma levels of lipids, lipoproteins and apolipoproteins in primary hypercholesterolemia. Minerva Cardioangiologica 37(12): 509-515, 1989

Differential effects of simvastatin and bezafibrate on apolipoprotein-defined high-density lipoprotein subfractions in patients with hypercholesterolemia. Current Therapeutic Research 57(1): 26-32, 1996

Effects of a brief treatment with bezafibrate on lipoproteins of the serum in patients with primary hypercholesterolemia. Giornale della Arteriosclerosi 10(2): 109-114, 1985

Lipoprotein changes induced by bezafibrate 200 mg t.i.d. and by bezafibrate in a slow release preparation 400 mg once a day in patients with primary hyperlipoproteinemia. Paoletti, R , D Kritchevsky And W L Holmes (Ed ) Proceedings in Life Sciences: Drugs Affecting Lipid Metabolism; Meeting, Florence, Italy, October 22-25, 1986 Xvi+451p Springer-Verlag New York, Inc : Secaucus, New Jersey, Usa; Berlin, West Germany 283-290, 1987

Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia. Clinical Therapeutics 11(3): 331-340, 1989

Effects of pravastatin on serum lipids, apoproteins, and lipoprotein (a) in primary hypercholesterolemia. Minerva Medica 85(6): 321-326, 1994